Nektar Therapeutics (NKTR) Return on equity 2016–2025
Nektar Therapeutics (NKTR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-182.6%FY2025 · since FY2016: -174.2% → -182.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -182.6% | +13.2 pp |
| FY2024 | -195.9% | +14.9 pp |
| FY2023 | -210.8% | -110.3 pp |
| FY2022 | -100.4% | -23.3 pp |
| FY2021 | -77.1% | -35.8 pp |
| FY2020 | -41.3% | -9.9 pp |
| FY2019 | -31.4% | -71.0 pp |
| FY2018 | 39.7% | +149.8 pp |
| FY2017 | -110.1% | +64.1 pp |
| FY2016 | -174.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NKTR financial trends
NKTR RevenueNKTR Net incomeNKTR Net marginNKTR Gross profitNKTR Gross marginNKTR Operating incomeNKTR Operating marginNKTR Operating cash flowNKTR Free cash flowNKTR Capital expendituresNKTR Stock buybacksNKTR Dividends paidNKTR Total assetsNKTR Total liabilitiesNKTR Shareholders’ equityNKTR overview →